Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-228 in Soft Tissue Sarcomas With mTOR Pathway Dysregulation
NCT02987959Phase 2Terminated
- Sponsor
- Fox Chase Cancer Center
- Start
- Feb 2017
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sapanisertib in soft tissue sarcoma (STS), sponsored by Fox Chase Cancer Center. Primary endpoint: Progression Free Survival Rate at 12 weeks. Started Feb 2017; status: terminated.
02
Drugs
sapanisertib
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT02987959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02987959.